[Treatment of hypersecretory ileostomy, gastrostomy and fistula of the small intestine with the somatostatin analog octreotide].
Hypersecretory stomas or fistulas are disabling conditions for the patients and a therapeutic challenge to the surgeons. Octreotide treatment is reported to reduce stoma output and the need for intravenous supplements. Octreotide treatment also reduces social disability due to postprandial hypersecretion causing frequent changes of stoma systems. Two patients with high output stomas and one patient with high output ileocutaneous fistula were treated with the somatostatin analogue octreotide. Reductions in stoma or fistula output from 48 to 62% were observed.
Lindsetmo
R O
RO
Kirurgisk avdeling Regionsykehuset i Tromsø.
Revhaug
A
A
D000328:Adult; D005260:Female; D005402:Fistula / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D005768:Gastrointestinal Hormones / Q000378:metabolism; D005774:Gastrostomy / Q000009:adverse effects*; D006801:Humans; D007081:Ileostomy / Q000009:adverse effects*; D007412:Intestinal Fistula / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000188:drug therapy* / Q000503:physiopathology; D012636:Secretory Rate / Q000187:drug effects; D012871:Skin Diseases / Q000175:diagnosis* / Q000209:etiology / Q000503:physiopathology
D005768:Gastrointestinal Hormones; D015282:Octreotide
Behandling av hypersekretorisk ileostomi, gastrostomi og tynntarmsfistel med somatostatinanalogen oktreotid.